He served as the chief medical officer for the Pharmaceutical Research and Manufacturers of America (PhRMA) before being named CEO of Callidus Biopharma, Inc., which he successfully guided through its initial drug discovery efforts to its eventual acquisition by Amicus Therapeutics. He holds MD and MPH degrees from the George Washington University, an MBA from Harvard Business School, and a bachelor of science in biomedical engineering from Johns Hopkins University.